Strategist Michael Antonelli joins Jared Blikre to break down the Fed decision and more at 2 P.M. ET Wednesday.
A phase 1/2 trial to initiate across a range of patient populations with RET-altered cancers
LONDON, June 22, 2022--(BUSINESS WIRE)--Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP0031, a next generation selective RET inhibitor (SRI).
Developed in partnership with Sichuan Kelun-Biotech Pharmaceutical Co., Ltd (Kelun-Biotech), EP0031 (known as A400 when in conjunction with Kelun-Biotech’s ongoing regional development) is a next generation SRI under development for the treatment of RET-altered cancers, with the first trials to focus on thyroid and non-small cell lung cancer. Kelun-Biotech has already commenced a clinical trial of EP0031 (A400) in China, which is progressing rapidly towards the dose expansion stage.
Approval of the IND is a significant step in the initiation of a global, modular Phase 1/2 trial to evaluate the safety, tolerability and efficacy of EP0031 in patients with advanced RET-altered cancers including patients who have not received prior treatment with first generation SRIs. The trial will include sites across the US and Europe and the first patient is anticipated to enter the dose escalation part of the trial in Q3 2022. Further regulatory submissions in the UK and EU are anticipated shortly to support the initiation of the trial in countries outside of the US.
Dr Rajan Jethwa, Chief Executive Officer & Founder of Ellipses, commented: "EP0031 offers the potential for a promising new treatment option that seeks to address some of the issues with first generation SRIs. Next generation SRIs offer the potential to expand the armamentarium against RET-driven cancers and further improve patient outcomes. This IND marks another important step for Ellipses. Our strategy is to advance the most promising cancer treatments to the clinic as soon as possible, and the clearance of this IND will allow us to rapidly move forward with our planned clinical trial of EP0031."
About EP0031 (A400) EP0031 is a potent next generation SRI with broad activity against common RET fusions and mutations, including solvent front resistance mutations. Therefore, EP0031 (A400) may overcome resistance mechanisms to first generation SRIs. In preclinical studies, EP0031 (A400) demonstrated favourable inhibitory activity against key RET kinases in-vitro and in-vivo. EP0031 (A400) also demonstrated good penetration of the blood brain barrier in animal models. An IND application for EP0031 (A400) was approved by China’s National Medicinal Products Administration (NMPA) in June 2021 and a Phase 1/2 trial is ongoing in China. In March 2021, Kelun-Biotech granted Ellipses an exclusive license for EP0031 (A400) in certain territories including the US and Europe, with Kelun-Biotech retaining certain rights in Greater China and part of the Asia-Pacific region.
About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the time it takes to advance lead products through clinical trials and reach patients.
For more information, please visit ellipses.life
About Kelun-Biotech Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., founded in 2016. Kelun-Biotech is committed to developing and commercializing innovative drugs for the treatment of cancer, autoimmune and other diseases with unmet medical needs.
Kelun-Biotech has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls) and clinical development capabilities. Leveraging the platform, the company has built a robust pipeline, one I/O molecule in NMPA NDA stage, three molecules (including one monoclonal antibody and 2 ADCs) in Phase 3 or pivotal clinical trials and an additional 10 molecules in early Phase 1 or 2 clinical studies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005564/en/
Ellipses Pharma Ltd Suzanne Wood media@ellipses.life www.ellipses.life
The Chester County company is working with the India-based developer of Covaxin to bring the Covid-19 vaccine to North America.
The strong immune responses against the Omicron subvariants in a new study reinforced Moderna’s plan to seek regulatory authorization to release an updated booster shot in August.
A Raleigh drug developer's stock dropped hard after the company said it would end a late-stage study for its co-lead drug candidate.
AbbVie (NYSE: ABBV) announced today that Health Canada has approved a change in the marketing authorization for MAVIRET® (glecaprevir/pibrentasvir) to include its use for the treatment in paediatric patients 3 to 12 years old, weighing at least 12kg to less than 45kg.1 MAVIRET is now approved as an 8-week, pan-genotypic (GT1-6) treatment for treatment-naïve, chronic HCV patients, without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older.1**
Is Johnson & Johnson stock a buy after the company unveiled positive results in cancer treatment this month? Is JNJ stock a buy?
The updated vaccine, which Moderna is hoping will be approved for use as a booster shot for the fall, is a bivalent vaccine, meaning it contains vaccine designed to target two different coronavirus variants - the original variant from 2020 and the Omicron variant that was circulating widely last winter. Moderna said that while the shot elicited a weaker response versus BA.4 and BA.5 than it does against the BA.1 subvariant it was specifically designed to combat, the data suggests the new shot could produce "lasting protection against the whole family of Omicron variants."
As much as we all want the pandemic to be over, it's not. Cases are spiking in many areas and although safety precautions have been lifted, trying to avoid COVID is still recommended because there can be long lasting damaging effects that harm overall health and lingering symptoms that can continue for months. Eat This, Not That! Health spoke with different virus experts who explain what to know about COVID right now, when to still wear a mask and places to avoid in an effort to prevent getting
A partnership to open a new research and manufacturing centre in the UK will mean over £1 billion in mRNA research investment.
U.S.-listed shares of AstraZeneca were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its primary endpoints in a Phase 3 clinical trial. AstraZeneca is developing eplontersen with Ionis Pharmaceuticals Inc. ; shares in Ionis were up 5.1% on Tuesday. The rare disease can cause nerve damage and motor disability and affects about 40,000 people worldwide, the companies said. They also said they plan to see
COVID cases are again surging in Europe, driven by the BA.4 and BA.5 subvariants of omicron that are deemed to be 10% to 15% more infectious than earlier variants and are spreading fast in Portugal, France, Germany, Italy, Spain, Greece, the Netherlands and Denmark.
(Reuters) -The U.S. Supreme Court on Tuesday rejected dialysis provider DaVita Inc's claims that an Ohio hospital's employee health plan discriminates against patients with end-stage kidney disease by reimbursing them at low rates in hopes they would switch to Medicare. In a 7-2 decision https://fingfx.thomsonreuters.com/gfx/legaldocs/byvrjaqorve/06212022davita.pdf authored by conservative Justice Brett Kavanaugh, the court ruled that Marietta Memorial Hospital's employee health plan did not violate federal law by limiting benefits for outpatient dialysis because it did so without regard to whether patients had end-stage renal disease.
Your blood type can reveal a lot about you like personality traits, but it can also indicate certain health issues you're at greater risk for such a cancer. Specific blood types have been associated with various cancers, however there are lifestyle choices you can make to help lower the risk according to experts. Read on to find out more—and to ensure your health and the health of others, don't miss Already Had COVID? These Symptoms May "Never Go Away". 1 Lung Cancer Dr. JB Kirby a doctorate-pre
Louisiana Senator Katrina Jackson's measure is a 'trigger bill' to outlaw abortion if the Supreme Court overturns Roe v. Wade.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, is pleased to announce the integration of the BD HealthSight™ Analytics Solutions in Eastern Health facilities. Eastern Health will become the first healthcare authority in Canada to integrate BD HealthSight™, which aims to reduce the use of antibiotics and other medications in addition to helping healthcare providers identify emerging infections among patients.
Leaders of the global scheme aiming to get COVID-19 vaccines to the world's poorest are pushing manufacturers including Pfizer and Moderna to cut or slow deliveries of about half a billion shots so doses are not wasted. COVAX, the World Health Organization-led scheme, wants between 400 and 600 million fewer vaccines doses than initially contracted from six pharmaceutical companies, according to internal documents seen by Reuters. While at first the initiative struggled for shots as wealthy nations snapped up limited supply, donations from those same countries later in 2021, as well as improved output from manufacturers - alongside delivery challenges and vaccine hesitancy in a number of countries – has led to a glut of vaccine in 2022.
According to John Hopkins Medicine, "Half of all American adults—including 70 percent of those age 65 and older—take a multivitamin or another vitamin or mineral supplement regularly," but are taking vitamins really healthy? Some experts believe vitamins are beneficial and help supplement nutrient deficiencies, but others say they're a waste of money. While that debate won't be settled anytime soon, many are in agreement that some vitamins can be harmful. Read on to find out more—and to ensure y
The Biden administration is writing a plan that would order cigarette manufacturers to cut nicotine levels.
Moderna said it would manufacture vaccines in the U.K. as part of a deal with the British government aimed at ensuring speedy access to mRNA vaccines in the event of future pandemics.
Moderna Inc (NASDAQ: MRNA) has released new clinical data on its bivalent (omicron) COVID booster candidate, mRNA-1273.214. One month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the omicron subvariants BA.4 and BA.5. The company is working on completing regulatory submissions in the coming weeks requesting to update the composition of the booster vaccine to mRNA-1273.214. mRN
Story at a glance Lung cancer remains one of the leading causes of cancer-related death in America, and disproportionately impacts vulnerable communities. Looking at data collected between 2004 and 2016, researchers assessed late-stage diagnosis rates among different racial/ethnic populations. After adjusting for insurance type, treatment facility type, and other factors, Black individuals were more likely…